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RIASSUNTO. Scopo Lo studio affronta problemi concettuali, metodologici e clinici della comorbiditä, aHa luce dei 
piu recenti studi epidemiologici. Inoltre viene valutata la causa potenziale e il ruolo patogenetico dei disturbi tempora­
neamente primari per la comparsa dei disturbi secondari. Risultati - I risultati disponibili fino ad oggi suggeriscono 
ehe la comorbiditä (a) non eun artefatto delle strategie di valutazione, dei campionamento 0 dei disegno, (b) especifica 
nei differenti disturbi, (c) eparticolarmente frequente nei disturbi affettivi e d'ansia, (d) influisce sistematicamente sull'an­
damento delle condizioni di comorbiditä e (f) potrebbe essere correlata con modelli di evoluzione dei sintomi. Conclusioni 
Einoltre evidente che forme specifiche di disturbi di ansia primaria comportano il rischio di sviluppare disturbi depres­
sivi secondari, aumentano la probabilitä di non remissione cosi come il numero di successivi episodi depressivi. 
PAROLE CHIAVE: comorbiditä, progressione dei sintomi, ansia, disturbi affettivi, disturbi da abuso di sostanze, 
epidemiologia. 
SUMMARY.Objective The paper discusses conceptual, methodological and c1inical issues of comorbidity from the 
perspective of more recent epidemiological studies. Further the potential causal and pathogenic role of temporally prima­
ry disorders for the onset of secondary disorders is evaluated. Results - The available data suggest so far that comorbidity 
(a) is not an artefact of assessment strategies, sampling or design features, (b) is specific in different disorders, (c) is par­
ticularly frequent in anxiety and affective disorders, (d) affects systematically the course of the comorbid conditions and 
(f) might be related to symptom progression models. Conclusions Furthermore, evidence is presented that specific forms 
of primary anxiety disorders affect the risk for secondary depressive disorders, increase the likelihood of non-remission as 
weH as the number of subsequent depressive episodes. 
KEY WORDS: comorbidity, symptom progression, anxiety, affective and substance disorders, epidemiology. 
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INTRODUCTION 
The heuristic value of the comorbidity concept for 
a better understanding of mental disorders was recog-
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nized long aga by Hippocrates. Scientific interest in 
this concept, however, emerged only fairlyrecently. 
This increasein attention- seems to be significantly re­
lated to (a) the introduction of explicit descriptive, op­
erational criteria for specific mental disorders (DSM­
III to DSM-IV- American Psychiatric Association, 
1980, 1987, 1994, ICD-I0 WHO, 1991) and (b) asso­
ciated shifts of paradigms in psychopathological re­
search (such as the neo-kraepelinian paradigm - Kler­
man, 1990). Although now frequently used in c1inical 
research and practice as weIl as epidemiology, the 
term comorbidity still remains poorly defined and 
lacks cIear conceptualization (Maser & Cloninger, 
1990). This paper briefly discusses critical issues of co­
morbidity and summarizes more recent epidemiologi-
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cal data concerning the frequency of current and life­
time comorbidity of mental dis orders as weIl as poten­
tial pathogenetic and c1inical implications. Tbis review 
is restricted to epidemiological studies focussing on 
anxiety and affective disorders. Other comorbidity 
findings for example in relation to other mental disor­
ders, somatic conditions as weH as personality disor­
ders will not be discussed. 
Some critics have c1aimed that comorbidity simply 
mightbe regarded as an artefact of our current DSM­
III-R- and ICD-I0-based descriptive diagnostic c1assi­
fication rules and thus reject tbis concept as useless 
for pathogenic and clinical purposes. Tbis position 
is shared particularly by those who prefer traditional 
nosological mo'dels"bier.arcbicai "classification 
schemes or more comprehensive main dimensions of 
psychopathology (Goldberg, 1996). Others, however, 
Table I. Critical issues in the assessment 0/ comorbidity. 
emphasize not only the value of comorbidity for noso­
logical issues, but also stress its more general impor­
tance for research and c1inical implications. As noted 
by Regier et af. (1992, p. 2), «comorbidity may modify 
the c1inical course of patients with the same diagnosis 
by affecting the time of detection, prognosis, treat­
ment selection, and posttreatment outcome of an in­
dex diagnosis». At tbis point, however, there are only 
few data available about the specific pathogenic, ther­
apeutic and prognostic implications of comorbidity 
(for a more detailed discussion see Wittchen, 1996). 
But in some areas, such as comorbidity between anxi­
ety and affective as weIl as substance use disorders, it 
has at least been c1early demonstrated that the pre­
sence of more than one disorder can interfere signifi­
cantly with the effectiveness of behavioral as weil as 
pharmacological treatments (i.e. Marks, 1985). 
I. Conceptual level: a) 
b) 
c) 
d) 
e) 
comorbidity = associations between descriptive classes of disorders in a given time frame 
co-occurrence = cross sectional associations between symptoms or syndromes 
disorders as defined by classification systems 
postulated subthreshold models 
application of hierarchical rules as suggested by diagnostic systems (i.e. DSM-IIIR, ICD-IO) 
2. Units of content: 
(Diagnostic coverage) 
Within any (or some) of the following groups: 
a) mental disorders and specific subtypes within dis orders 
b) personality disorders 
c)· somatic disorders 
d) psychosocial impairments and disabilities or between any of the above 
3. Time window: a) 
b) 
c) 
d) 
cross-sectional (2 weeks, I month, 6 months, etc) 
longitudinal (1 year, 3 years, etc) 
lifetime (over the whole lifespan) 
accuracy of temporal resolution 
4. Assessment method: a) 
b) 
c) 
d) 
e) 
unstructured (nosological) diagnoses ICD-9) 
loosely structured clinical diagnoses (DSM-III) 
structured diagnostic interviews (SCID) 
standardized diagnostic interviews (DIS,CIDI) 
specific comorbidity instruments (memory probes) 
5. Design & analysis a) 
b) 
c) 
sampling procedure 
correction for base rates 
consideration of confounding factors 
6. Explanations of Comorbidity Artefact hypotheses 
.. Assessment instruments 
.. Random 
.. Help-seeking 
.. Population 
True associa tions 
.. 
.. 
.. 
.. 
Causal 
Common etiology 
Alteruative manifestations 
Developmental stages 
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CRITICAL ISSUES IN EV ALUATING 

COMORBIDITY 

The first difficulty in determining the implications 
of comorbidity is the definition and usage of the 
term itself. Wittchen (1996) notes that there are mul­
tiple definitions of comorbidity, making direct com­
parisons of studies sometimes difficult. Besides defi­
nitions which use the term within the context of no­
sological considerations (Feinstein, 1970), more ade­
quate definitions of comorbidity can be derived from 
Boyd et al. (1984) defining comorbidity from an epi­
demiological perspective «as the relative risk of a 
person with one disorder to have another disorder» 
as weIl as more comprehensively by Burke et al. 
(1990). The latter defined comorbidity «as the pre­
sence of more than one specific disorder in a person 
in a defined period of time». This general definition 
provides information regarding what is being mea­
sured (disorders and not illnesses): it is applicable 
for longitudinal, lifetime as weil as cross-sectional 
measurements and it covers all possible conceptual 
frameworks. Therefore, it can be applied to many 
of the more recent epidemiological and clinical stu­
dies studying the frequency and the meaning of co­
occurrences of different diagnostic classes, defined 
in ICD-lO or DSM-IIIR. 
A number of other factors complicate the inter­
pretations of comorbidity findings (Table I): 
1. Symptoms, syndromes or disorders. Comorbid­
ity in many publications is sometimes used to refer 
to associations between symptoms and syndromes 
rather than co-occurrences of specific diagnostic 
classes of codified disorders in ICD-lO or DSM­
III-R disorders. This has led to considerable confu­
sion, especially when the diagnostic rules are not 
clearly specified. As useful as this symptom and syn­
drome approach might be in studies of clearly de­
fined subthreshold conditions, as weIl as the determi­
nation of course patterns, for the concept of comor­
bidity it has led to confusion. 
2. Number of diagnoses considered. Furthermore 
studies often differ with respect to the number of dis­
orders they take into consideration, compromising 
their comparability to other studies when looking 
into the frequency and the patterns of comorbid con­
clusions. For example, there is little comparability in 
the specific sub types of anxiety as weIl as substance­
specific abuse and dependence diagnoses. In the case 
of anxiety disorders, for example, no epidemiological 
study included posttraumatic stress disorder (except 
for Kessler et al., 1994), separation anxiety disor­
der, adjustment dis orders with anxious mood or aty­
pical forms of these disorders. For substance use dis. 
orders, studies vary with regard to the type of sub­
stance included, most leave out nicotine dependence 
completely, substance-specific comorbidity patterns 
are: rarely reported, and most studies have limited 
analyses to alcohol use disorders. Furthermore, 
there are almost no studies that control comorbidity 
findings for substance-induced mental disorder that 
might explain a substantial proportion of artefac­
tual comorbidity. 
3. Comorbidity between axes. Generally comorbid­
ity can be considered between different forms of 
mental disorders and specific subtypes within .one 
group of disorders, between personality disorders, 
somatic disorders and psychosocial impairments 
and disabilities or between any of these groups. 
4. Time window. The «time window» under con­
sideration is another factor influencing findings. Re­
sults of comorbidity have to be clearly differentiated, 
whether they depend upon cross-sectional (2 weeks, 
1 month, 6 months, etc.), longitudinal (1 year, 3 
years, etc.) or lifetime (over the whole life span) as­
sessment of symptoms or syndromes, resulting in dif­
ferent prevalences and different patterns of comor­
bidity. Further difficulties arise in the accuracy of re­
solution when determining which disorder is primary 
or secondary, because of questionable validity of ret­
rospectively assessed age of onset information for 
each disorder. 
5. Instrument effects. The method of diagnostic 
and comorbidity assessment and the derivation of 
specific diagnoses are another critical area. A 
WHO collaborative study (Wittchen, 1996) found 
that standardized instruments usually generate 2-3 
times as many diagnoses. aso assigned. by a clinician, 
who tends to summarize features of several diag­
noses under one principal diagnosis as weIl as ne­
glects past and lifetime diagnoses not present at the 
time of the investigation. However, even if there is 
agreement on the use of a specific standardized diag­
nostic tool, the instrument can be used differently. 
Studies often differ, for example, in the way DSM­
III-R hierarchy rules (exclusion rules criteria) are ap­
plied, significantly affecting the resulting prevalence 
rates. Furthermore, studies using the CIDI fre­
quently differ with regard to the diagnostic sections 
covered. Many do not evaluate all anxiety or soma-
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toform disorders covered by this instrument, result­
ing in considerably lower comorbid frequencies. 
6. Design differences are another significant 
source of discrepancies in comorbidity rates. Cross­
sectional, follow-up and longitudinal designs as weB 
as age co hort studies obviously affect comorbidity 
findings simply by covering different time periods 
of risk. Further differences' become evident when 
looking at different sampling strategies. Studies in 
clinical settings usually reveal twice as high rates of 
comorbidity as compared to those found in the gen­
eral population (Wittchen & Essau, 1989; Wittchen 
et al., 1991). This might reflect the fact that those 
with multiple disorders are more likely to seek he1p 
and receive treatment (Heizer&:' Pryzbeck, '1988) 
and underlines the general characteristics of all clin­
ical sampies to be highly selective in the clinical pat­
terns. Therefore, epidemiological studies based on 
community sampies are probably more likely to pro­
vide a representative view of comorbidity patterns 
that is unbiased in terms of selective effects. 
FREQUENCY OF COMORBIDITY 
IN EPIDEMIOLOGICAL STUDIES 
Most epidemiological surveys in the past 15 years 
have used a standardized diagnostic interview 
(mostly Diagnostic Interview Schedule, DIS Ro­
bins et al., 1982, or the WHO-Composite Interna­
tional Diagnostic Interview, CIDI, or modifications 
thereof - Wittchen, 1994) based on explicit diagnos­
tic criteria. Despite some degree of methodological 
differences these studies conclude that about 50% 
of all cases have more than one disorder in their life­
time, with almost one third having comorbid condi­
tions in the past twelve months (Kessler et al., 1994: 
Merikangas et al. , 1996). These studies also con­
firmed, by using appropriate statistical measures 
(odds ratio), that these comorbidity rates can not 
been explained by chance or regarded as an arte fact 
by sampling or instrumentation (see British Journal 
of Psychiatry, vol. 168, Supp1. 30, 1996). In the fol­
Jowing thr.ee .paragraphs .some selected findings will 
be presented that rnight demonstrate specifically 
the potential etiopathogenic and clinical importance 
of comorbidity. 
Auxiety disorders: lessons from epidemiological studies 
Three examples have been selected for this area: 
symptom progression, the pathogenic importance 
of early versus 'latepanic attacks, and suicide at­
tempts. 
From the Study of Comorbidity to the Study of 
Symptom "Progression: The majority of studies fo­
cussed on anxiety disorders that have been shown 
to be significantly associated (a) among each others 
(Magee et al., 1996), with lifetime Odds ratios ran-
Table H. Comorbidity of anxiety disorders with depressive (Iifetime and 12-month) and substance use disorders in a prospective longitu­
dinal (MFS) (Wittchen et al., 1992) and a eross-seetional study (NCS) (Kessler et al., 1994). 
DSM Diagnosis & StDdy Depression Iifetime Depression 12-months Substance disorder 
% OR % OR % OR 
Generalized Amtiety MFS 56.2 6.8 41.1 9.2 28.6 2.1 
NCS 62.4 9.7 38.6 13.9 32.3 2.9 
Agoraphobia MFS 41.2 4.2 22.3 4.6 24.3 11.2 
NCS 45.9 4.8 27.8 5.9 36.3 1.6 
Specifie Phobia MFS 39.8 4.9 18.1 4.6 26.1 4.1 
NCS 42.3 4.6 23.7 5.3 39.4 2.0 
Social Phobia MFS 31.3 8.1 n.a. 41.3 6.8 
NCS 37.2 3.7 n.a. 39.6 2.0 
Panie Disorder MFS 62.8 15.8 48.3 9.6 32.4 n.a. 
NCS 64.1 8.2 41.2 .9.1 39.4 4.2 
PTSD NCS 47.9 53 38.2 8.7 51.4 6.7 
n.a.: data not available 
(from Wittchen & Vossen, 1995) 
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Symptom PrecursorlConsequence 
bl%glca/ vu/nerabilfty 
cognitive vu/nerabi/ity 
oeeurenee spontaneous panie sensitization 
reeur rent panie attaeks Panie disorder 
subsequent avoidanee behavior Agoraphobia 
ex peetation anx iety (Generalized Anxiety disorder) 
demoralization Major Depression 
sei f-hel p strateg ies Substanee Abuse 
Figure 1. - Symptom progression: from pank to depression. 
ging from 3.8 (social phobia and GAD) to as high as 
12.3 (GAD and panic disorder) as weIl as (b) with 
other mental disorders. As an example for these find­
ings table II compares the findings of a prospeetive 
longitudinal 7-years study (Wittchen & Von Zers­
sen, 1987) with the more recent findings from the 
eross-sectional National Comorbidity Survey (NCS 
Kessler et a/., 1994). Although these two studies 
were conducted in different countries, with slightly 
different diagnostic instruments, different diagnos­
tk systems (DSM-III and DSM-III-R) and are 
hardly comparable with regard to sampie size 
(NCS more than 8 000 respondents, MFS only 
1366 subjects) there is surprisingly high agreement. 
Particularly strong associations (Odds) are evident 
for cutrent and lifetime affective disorders, with gen­
eralized anxiety disorders and pank disorders. Con­
siderably lower but still significant odds ratios were 
found for substance disorders. 
The strong interest in anxiety disorders was prob­
ably stimulated by two interrelated facts. One is the 
finding that panic attacks and simple and social pho­
bias usually start early in adolescence and thus could 
be considered a primary disorders, the other is the 
suggestion of so-caIled symptom progression mod­
els (SPM). 
Such models (figure 1) suggest a systematic pro­
gression (for example Klein, 1981) from an initial 
spontaneous panic attack to the development of 
agoraphobia, expectation anxiety (GAD) to. demor­
alization (Major depression) and helpseeking (sub­
stance abuse). Similar models have recently devel­
oped for pathways from phobias into depression 
(Wittchen & Vossen, 1995). Retrospective analyses 
from cross-sectional studies as weIl as the few avail­
able longitudinal epidemiological studies (Angst et 
al., 1990) have provided some evidence for such 
pathways, including the demonstration that panic 
attacks frequently precede the development of agor­
aphobia, as weIl as that anxiety disorders usually 
precede depressive and substance use disorders 
(Merikangas et al., 1996). Furthermore, we could re­
cently demonstrate that primary anxiety disorders 
affect significantly the length'of depressive episodes 
and the number of subsequent depressive episodes 
over an observation period of seven years (Wittch­
en & Vossen, 1995). 
Different pathogenie meehanisms in late versus 
early onset panie: Based on findings suggesting that 
symptom progression might be"different 'in subjects 
with a typical, relatively early age of first onset in 
late adolescence and early adulthood and those with 
a later onset in life (Burke et a/., 1990), we recently 
subtyped subjects according to this bimodal age of 
onset distribution into early (first onset prior to 
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age of 25) and late onset panicers (after age of 25). 
When examining their spontaneous course of illness 
over 7 years we found: I) a significantly higher symp­
tom score for late onset panic attacks due to more 
frequent symptoms related to the respiratory and 
cardiac system as weH as fear of dying, (2) a consid­
erably elevated risk for developing multimorbidity 
(having affective and substance and somatoform dis­
orders) in the late onset group and (3) a significantly 
more rapid development of secondary disorders in 
the late onset group. In the early onset group usual­
ly years went by before the development of second­
ary disorders (4) Further the early onset group had 
considerably higher odds to develop agoraphobia 
as well as o,ther. phobias(W.ittchen& Perkonig'g"sub­
mitted for publication). 
Comorbidity, suicidal ideation and suicide at­
tempts: Most studies in suicide research have been 
focussing on the relationship with depressive disor­
ders. Only recently, stimulated by more sophisti­
cated analyses of epidemiological datasets (Weiss­
man et al., 1989) the critical role of comorbidity spe­
cifically with anxiety disorders was examined. These 
studies showed thai cases with pure major depression 
have no or only slightly elevated odds for suicide at­
tempts as compared to subjects with no mental disor­
ders, whereas lifetime anxiety dis orders comorbid 
with depressive dis orders, and particuIarly those 
with panic attacks, have highly elevated odds for sui­
cide attempts. 
Depressive disorders: lessons from epidemiological 
studies 
There are a fairly large number of epiderniological 
studies that have documented high comorbidity rates 
in dep~essive disorders. Few studies have, however 
gone beyond by examining temporal relationship 
and other implications of this comorbidity. One of 
the most detailed studies is the NCS. Kessler et al. 
(1996) recently demonstrated (Table III) on the ba­
sis of his assessment with the UM-CIDI, by taking 
into account various anxiety disorder (inc1uding 
PTSD), substance use dis orders (excluding nicotine 
dependence) as weIl as dysthymia and conduct disor­
der, that onIy few major depressive disorders are 
pure; 26.0% of his general population sampie aged 
15 to 55 had a pure lifetime depressive dis order, 
with only few of the comorbid cases having a pri­
mary depressive disorder. Based on discrete-time sur­
vival models in which information about age of onset 
was used to study the time-Iagged effects of earlier 
disorders on the subsequent onset of secondary de­
pression the authors found: 
(I) 	67.9% of cases with secondary depression are as­
sociated with a temporal primary anxiety disor­
der, 19.2% with primary substance use dis order 
and L8% with primary dysthymia and 12.6% 
with primary conduct disorder. 
(2) The average difference between onset were very 
short for GAD and panic disorder, suggesting 
that these anxiety disorders are fairly quickly fol­
lowed by depression (average of 1.5 years). Con­
siderably longer time intervals were found for 
.,primary"agoraphobia (10.6 years), primary sim­
ple phobia (13.6 years) as weIl as conduct disor­
der (11.8 years). Primary substance use disorder 
precede secondary depression on average by 4.3 
to 6.5 years, depending of the substance. 
(3) 	Primary anxiety disorders also significantly in­
crease the odds of a more persistent course of de­
pression and are also clearly related to higher 
self-perceived interference with life and activ­
ities, suicide attempts and hospitalization. 
(4) 	Primary'substance use disorders are associated 
with interference and hospitalization but not 
with suicide attempts. 
Table llI. Prevalences o/lifetime pure, primary and secondary ma­
jor depressive disorders with standard errors. 
Pure Primary Secoodary 
% SE % SE % SE 
Total 26.0 2.5 12.2 1.2 61.8 2.6 
Wornen 30.1* 3.0 12.2 1.6 57.7* 2.9 
Men 18.6 2.7 12.1 2.2 69.3 3.4 
# respondents with lifetime MDD and lifetirne dysthymia only we· 
re coded as pure 
* p < 0.05 wornen versus rnen 
(frorn Kessler et al.,1996) 
These data for the first time confirmed with more 
sophisticated statistical analyses earlier assumptions 
and observations (Wittchen & von Zerssen, 1987; 
Wittchen & Vossen, 1995) about the effect of comor­
bidity in depressive disorders. But of course it should 
b~ mentioned that these analyses are derived from 
retrospective data from cross-sectional study and 
await further validation in prospective studies. 
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Substance use disorders: lessons from epidemiological 
studies 
There is agreement between the two major US­
American studies, the NCS and the ECA that (1) 
over half (51.4%: NCS; 53.1 %: ECA) of those with 
any substance use disorder have experienced other 
forms of mentai disorders at some time in their life. 
(2) Approximately 36.6% of those with any lifetime 
alcohol use dis order experienced some mental disor­
der at some time in their life, a rate which is more 
than double that found in those without an alcohol 
disorder. (3) Furthermore, respondents with alcohol 
or drug dependence were more Iikely to suffer from 
a comorbid (either lifetime or l-year) psychiatrie dis­
order than those with alcohol or drug abuse. (4) Ma­
jor depression was often evident in those with alco­
hol or drug dependence although it remains uncIear 
which of these disorders came first and which sec­
ond. (5) Slightly higher associations were found for 
anxiety disorders, with phobia as the most prevalent 
and GAD and panic disorder demonstrating the 
strongest association. (6) Adolescent conduct disor­
der and adult antisocial personality disorder dis­
tinctly stand out as being very frequently found in 
those with substance use dis orders across both sub­
stance abuse and dependence. (7) PTSD is strongly 
related <>nly to drug dependence but not abuse nor 
aIcohol dependence. (8) Mania and schizophrenia 
have both a strong and consistent relationship to al­
cohol as weIl as drug dependence, but not to abtise 
(Wittchen et al., 1996). 
Most of these findings and conclusions have been 
replicated in other studies such as the MFS (Wittch­
en et al., 1992), the Zurich cohort study (Angst et al., 
1990)or the epidemiological study in Edmonton, Ca­
nada (Russe! et al., 1994). 
Time sequence: What comes irrst? In terms of the 
potential causal role of other mental disorders as 
risk factors for substance use disorders it is of spe­
cial interest to investigate the order in which disor­
ders develop over life. In the vast majority of respon­
dents of the above mentioned studies the onset of 
other mental disorders clearly preceded the onset of 
the substance use disorder. This sequence effect 
was especially strong and consistent for conduct dis­
order and anxiety disorders and least strong (and 
even reversed in men) for affective disorders, schizo­
phrenia, mania and PTSD. 
Affective disorders in both the ECA and the NCS 
occurred at an almost equal frequency either before 
or after the onset of the substance use disorder. 
48.4% of comorbid respondents reported the affec­
tive disorder occurred first, 40.3% reported that 
the substance use dis order occurred clearly. befm:e 
the onset of the affective disorder. 
On the other hand, 79.3% of substance use-/anxi­
ety disorder comorbid· cases reported that their anxi­
ety disorder started first while only 16.6% reported 
that the substance use disorder started first. The ef­
feet for conduct disorder (and antisocial personality 
disorder) was even stronger, 89.3% reporting that 
the conduct or antisocial personality disorder began 
first and only 7.5% reporting that their substance 
use disorder began first. For comorbidity within 
the substance use disorders, the ECA further indi­
cated on the symptom level that «in 43.3% of comor­
bid cases the age of onset for the first alcohol pro­
blem was lower than the age of first drug problem; 
in 36.1 % the age of the first drug problem was lower 
than the age of first alcohol problem» (Anthony & 
Heizer, 1991, p.148). 
This suggests that mental disorders, particularly 
conduct and anxiety disorders, might play an impor­
tant pathogenic role in the development of the sub se­
quent substance use disorder, but Kessler et al. (in 
preparation) warn that «it is important to recognize 
that neither temporal order nor prediction can be ta­
ken to imply causa! priority». They point out that a 
temporally prior disorder may either direct1y or in­
directly influence the development of a later disor­
der, or a third variable may be the causal variable 
in causing comorbid disorders. 
CONCLUSIONS 
The above cited selected findings have underlined 
the usefulness of the comorbidit~.concept as a new 
way of looking into the longitudinal and develop­
mental aspects of mental disorders. Furthermore it 
has become evident that the comorbidity concept 
might have implications simply documenting the cur­
rent overlap of conditions and requires more sophis­
ticated design and statistical models than previously 
thought. The full explorationof mechanisms of co­
morbidity requires (a) more syndrome-focussed pro­
spective longitudinal studies and (b) an interdisci­
plinary approach to investigate nosology, assess­
ment and underlying models of comorbidity. In this 
respect study designs are needed that are partially be-
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yond the scope of more traditional clinical and epi­
demiological studies which comprise so far the bulk 
of comorbidity research. Family (Merikangas, 
1990; Maier et al., 1994) and twin studies (Kendler, 
1996; Andrews, 1996) as weil as experimental tests 
of hypotheses in random subsampies of high-risk 
pro bands sampled from epidemiological studies 
might be most important tools. 
Similar to the few available prospective longitudi­
nal epidemiological studies they can distinguish be­
tween several of the above sources of comorbidity. 
Furthermore, prospective studies can examine more 
precisely the longitudinal stability, the order of on­
set of disorders (Wittchen & Essau 1989; Angst et 
al., 1990; Caron,,& Rutter, 1991), and,.th;us.uru:a.vel 
different pathways into several conditions of psycho­
pathology. In light of the tremendous variability of 
findings with regard to biological parameters a 
more precise specification of comorbidity patterns 
might also be a helpful strategy to identify more spe­
cific common biochemical markers relevant in the 
aetiology of specific mental disorders as weIl as co­
morbid conditions. 
But several caveats for epidemiological surveys of 
comorbidity phenomena should also'be addressed. 
The danger of premature artefactual explanations 
of comorbidity for example between substance use 
disorder and other forms of mental disorders be­
comes evident if we take into account that substance 
use might not only be used by the respondents to 
minimize psychiatric symptomatology (the use of 
substances as a form of 'self-medication') (Stock­
weIl et al., 1983), but also that the long-term use of 
certain substances (for example alcohol) can lead to 
symptoms of depression and anxiety. At this point 
almost no published epidemiological data are avail­
able to determine in detail these alternative explana­
tions. 
Which model fits best? We should keep in mind 
that there are numerous possible mechanisms in­
volved in comorbidity. To discuss those more con­
cretely we focus on substance use comorbidity: 
- Disorder APredisposes to Disorder B (A =} B) 
A primary disorder may direct1y predispose to the 
development of a secondary disorder. In a first ex­
ample a person with a childhood onset of social pho­
bia might have used alcohol or tobacco for alleviat­
ing stress-related symptoms in sodal situations, slip­
·ping-after years into patterns of abuse or depen­
dence. This pattern has recently been found by 
Wittchen & Beloch (submitted for publication)_ Vice 
versa, substance use disorders can raise the likeli­
hood for developing amental disorder. Rosen & 
Kosten (1992) found that cocaine use can precipi­
tate panic dis order in patients with no previous his­
tory of panic attacks. Cottler et al. (1992) also 
found in their study that drug users experienced 
moretraumatic events and were more likely to 
meet criteria for PTSD in later life. The ECA and 
NCS have both asked respondents to retrospectively 
assess the onset of their symptoms and found that 
some dis orders precede the onset of others, how­
ever, there is the danger of a retrospective recall 
bias. In a study whkh aimed to minimize tbis recall 
.bias by .. asking .youngerpeople about the onset of 
their disorders, Christie et al. (1988) found that in 
almost 75% of the young respondents in their sam­
pIe, anxiety or depressive dis order clearly began be­
fore the substance use disorder, suggesting that the 
mental disorder was 'causal' in the development of 
the substance use disorder. Other examples include 
agoraphobia developing after the onset of pank dis­
order as a result of the disabling fear of attacks in 
situations where help is unavailable and escape is im­
possible (Klein et al., 1987). This disabling picture of 
panie and agoraphobia avoidance has been found to 
be significantly related to the subsequent develop­
ment of benzodiazepine abuse (Wittchen& von Zers­
sen, 1987) or chronie mixed anxiety-depression, 
which ean occur when unremitting chronic anxiety 
leads to feelings of hopelessness and helplessness 
(Akiskal, 1990), resulting in full major deptessive 
episodes (see below). 
Either A or B May Predispose to the Other (A {:} B) 
It is also possible that either of two disorders pre­
disposes to the development of the other. One of the 
strongest comorbidity associations has been found 
for substanee use dis orders with comorbid conduct 
disorders or antisocial personality dis order (Kessler 
et al., 1996). Here evidence suggests that conduct dis­
order most frequently can cause substance use disor­
der, but vice versa substance use disorders can also 
trigger antisodal personalitydisorder&, such as in co­
caine or heroin dependence (criminal acts in order to 
get the substance), although there is less evidence of 
this last association being the predominant picture 
. when conduct disorder is being controlled for (Kess­
ler et al., in preparation). Other examples are pro­
vided by «self-medication» in anxiety. Substance 
use and abuse may develop as a-means of self-medi­
cating behavior to cope with anxiety symptoms: 
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long-term use of substances in turn can lead to in­
creased anxiety levels (Kushner et al., 1990). 
- A Key Anteeedent. Factor b. Specijie to Different 
Disorders (X::} A or ::} or ::} C) 
One factor may cause different disorders with dif­
ferent ·probabilities. For example the occurrence of 
spontaneous panic attacks (as a key feature in panic 
disorder) could be regarded as one key antecedent 
factor not only for the development of panic disor­
der, agorapho,bia. or other anxiety disorders, but 
also as an more general indicator for an assumed 
vulnerability that puts subjects at risk for develop­
ing several severe forms of mental disorders as weil 
as substance use disorders. Models of tbis type have 
been proposed as «symptom progression models» by 
Klein et al. (1987) or Wittchen & Vossen (1995). 
Other examples include personality disorders such 
as conduct disorder. Personality features of conduct 
disorder or in later age of antisocial personality can 
lead to earlier usage and dependence of drugs as weil 
as other forms of mental disorders (depression, psy­
chotic disorders). In one example of such an investi­
gation, Nace et al. (1991) found at a syndromallevel 
of analysis that subjects with personality disorder 
were more extensively involved in substance abuse 
and differed in their patterns of alcohol use. 
- One or More Antecedent Factors Predispose to Dis­
linet Disorders (X+ Y => A, X + Z => B) 
For this pathway, biological, social and cognitive 
factors have been hypothesized to act as general vul­
nerability factors (X) that may lead in ca se of the 
event Y or Z to the development of dis order A or 
B. Kessler et al. (in press) recently proposed from a 
sociological perspective that «common causes of dif­
ferent psychiatric disorders, such as community con­
text, stress and lack of social support lead to comor­
bidity (National Institute of Mental Health, 1993)>> 
(p. 11). In its more general. f{>Fm this· fmlFth pattern­
resembles most closely the many «vulnerability 
stress models» suggested for headache, psychotic dis­
order as weIl as affective disorders. 
Other types of antecedent factors are genetic pre­
disposition and vulnerability markers. Dinwiddie & 
Reich's (1993) review of family genetic studies led 
them to conclude that alcoholismand other sub .. 
stance dependence run in families. Furthermore, 
there is strong evidence for genetic factors playing 
a role in alcoholism and weaker though consider­
able evidence for genetic factors in other [orms of 
substance dependence (Merikangas et al., 1992). Fa­
milial associations between alcoholism and certain 
anxiety syndromes (most notably agoraphobia) are 
also evident (Dinwiddie & Reich, 1993; Wesner, 
1990). Ingraham & Wender (1992) found a signifi­
cantly greater incidence of affective disorders and 
substance abuse in the biological relatives of adop­
tees with' affective disorders. Furthermore, this was 
dependent upon sex; female relatives of those with 
affective disorders were at greater risk for affective 
disorders while males were at greater risk for sub­
stance abuse. Luthar et al. (1992) studied the sib­
lings of opioid addicts and ascertained that these sib­
lings were at high risk for the development of various 
disorders, particularly ASPD and substance abuse. 
The presence of a major psychiatric disorder further 
increased (above the risk already afforded by being a 
sibling of an addict) their risk of developing sub­
stance abuse. 
Table IV. Possible risk/protective factors. 
Stable susceptibility Transient precipitative 
and protective factors or supportive faeton 
Reritable genetic factors genetic (genes expressed at 
specific ages) 
Acquired biological faetors nongenetic biological factors 
(trauma, toxicity) (toxins, weight loss, illness) 
Farnilial psychosocial' fäetörs psychosocial factors (psycho­
(sociallearning, conditioning) dynamic, sociocultural, condi­
tioning, eognitive) 
Nonfarnilia psyehosoeial fac­
tors (individ uat' experience) 
(from Wittehen, 1996) 
It is most likely that no single explanation suffices 
for an explanation of comorbidity in general; rather a 
number of these paths to comorbidity might playa 
role which additionally may vary from disorder to dis­
order. The path to comorbidity that is followed is 
likely ,10 dep~ud not only ou. the type of primary dis­
order but also a variety of other factors (see table IV). 
Reservations against comorbidity: So why has the 
comorbidity approach been challenged several times 
in the literature? One reason is probably that the 
term comorbidity has been misleading for many clin­
iciansbecause it, incoFpgratesthe word morbus, asso­
ciated with the medical illness model and nosological 
considerations (Van Praag, 1996). However, it actu­
ally addresses in the field of mental disorders primar­
ily descriptive classes of disorders (thus a better term 
would be co-disorder). Clinicians educated in the ba-
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sis of the traditional classification models for psy­
chiatrie disorders (such as ICD-9) usually find it dif­
ficult to switch from the more hierarchical nosologi­
cal illness model to the more descriptive «atheoreti­
cal» classification schemes chara.cteristic of DSM­
IHR and the new ICD-I0. While the traditional 
models have laid emphasis on the current state and 
I . 	 principal diagnoses in a more hierarchical Wl?-Y (or­
ganic psychoses, psychosis, neurosis, addiction per­
sonality disorders, adjustment disorders), the mod­
ern classification schemes for mental disorders de­
leted many of the hierarchical rules and nosological 
implications, emphasizing that most diagnoses re­
quire assessment of symptoms and syndromes over 
the whole life span in a descriptive .way ..,This,neces­
sarily results not only in a substantially higher num­
ber of possible diagnoses in the classification 
schemes, but also, due to the explicit diagnostic cri­
teria and lack of hierarchical diagnostic rules, in a 
higher number of diagnoses per patient. This descrip­
tive lifetime approach of classifying specific disorders 
instead of broader conceptionally assumed «ill­
nesses» has increased the notoriously low reliability 
and ultimately as is hoped - will also improve 
the validity of diagnosesof mental disorders. At 
the same time it has brought the field, particularly 
in the area of affective-, anxiety- and substance dis­
order research, closer to the current basic research 
paradigms in neurobiology and experimental as weIl 
as cognitive psychology. It furthermore matches 
more c10sely the principles of the functional diagnos­
tic approach in behavior therapy that takes into ac­
count the lifelong (learning and problem) history of 
a case. 
Another source of reservations expressed against 
the new c1assification schemes and comorbidity, as 
weIl as the diagnostic instruments supporting the rig­
oro:us derivation of diagnoses and comorbidity pat­
terns, stem from the lack of data supporting the cHn­
ical usefulness for prevention, treatment and rehabi­
litation. Despite many hints that comorbidity might 
be a useful concept for research and particularly 
the identification of causal and pathogenic path­
ways, there is at this point still a lack of coherent the­
oretical models allowing an integration of comorbid­
ity findings. Thus the treatment and management 
implications of comorbidity necessarily are highly 
specula,tive and poorly supported by data at least 
in the field of substance dependence and therapeutic 
interventions. In the field of anxiety disorders (re­
view: Wittchen & Vossen, 1995) and more recently 
also in the field of affective disorders (Regier et al., 
1990), however, comorbidity concepts have helped 
not only to sharpen the structure of therapeutic in­
terventions but also contributed to an increased ef­
fectiveness. 
For the field of substance use disorders, the c1in­
kai utility of comorbidity considerations still re­
mains to be tested. We have given a couple of exam­
pies of how and in what areas this step of further ex­
ploration is currently being taken. Most of these 
steps mean sorting out the (causative) pathogenetic 
pathways in which specific mental disorders are in­
terrelated. Prospective longitudinal epidemiological 
and family genetic studies, preferably in epidemiolo­
gical sampIes, will probably be an essentiat"first step 
to resolve some of these issues. They will allow in the 
next step, along with studies in c1inical sampies, to 
determine how comorbidity affects the cHnical 
course and ultimately the effectiveness of treatment 
strategies. 
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